A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity

NCT07693868 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Elevated High-sensitivity C-reactive Protein (hsCRP)

Interventions

DRUG: NNC6022-0004
DRUG: Placebo

Sponsor

Novo Nordisk A/S